News | May 20, 2023
Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Zidavi is recommended by the Infectious Disease Society of America
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
He holds a Bachelor’s Degree in Science and has joined the company in 2012 and has over 10 years of experience in pharmaceutical industry
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)